Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Research & Development: 2013-2024

Historic Research & Development for CytomX Therapeutics (CTMX) over the last 12 years, with Dec 2024 value amounting to $83.4 million.

  • CytomX Therapeutics' Research & Development fell 28.38% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.3 million, marking a year-over-year decrease of 29.21%. This contributed to the annual value of $83.4 million for FY2024, which is 7.34% up from last year.
  • As of FY2024, CytomX Therapeutics' Research & Development stood at $83.4 million, which was up 7.34% from $77.7 million recorded in FY2023.
  • Over the past 5 years, CytomX Therapeutics' Research & Development peaked at $114.2 million during FY2021, and registered a low of $77.7 million during FY2023.
  • In the last 3 years, CytomX Therapeutics' Research & Development had a median value of $83.4 million in 2024 and averaged $90.9 million.
  • As far as peak fluctuations go, CytomX Therapeutics' Research & Development tumbled by 30.42% in 2023, and later rose by 7.34% in 2024.
  • Yearly analysis of 5 years shows CytomX Therapeutics' Research & Development stood at $112.9 million in 2020, then rose by 1.11% to $114.2 million in 2021, then fell by 2.23% to $111.6 million in 2022, then plummeted by 30.42% to $77.7 million in 2023, then increased by 7.34% to $83.4 million in 2024.